

## Press Release

---

### **TetraKit Technologies Announces Leadership Transition to Support Next Phase of Growth**

**Copenhagen, September 8, 2025** – TetraKit Technologies today announced a strategic leadership transition, effective from September 1, 2025, as the company enters a new phase of development focused on early human trials, translation, and increased emphasis on automation and CMC development and scaling.

After serving as Chief Executive Officer for four years, **Andreas Ingemann Jensen** has stepped down as CEO to assume the role of **Chief Operating Officer (COO)**. In this new capacity, Andreas will continue to play a vital role in overseeing TetraKit's operational excellence and execution.

**Matthias Herth**, previously Chief Scientific Officer (CSO), has been appointed the new **Chief Executive Officer (CEO)**. Matthias contributes with deep scientific expertise and strategic vision, positioning TetraKit to navigate the company's upcoming clinical and technological milestones.

In addition, **Umberto Maria Battisti** will assume the position of new **Chief Scientific Officer (CSO)**. Umberto's experience and key contributions to the Company's technology will be instrumental in driving TetraKit's innovation agenda as the company transitions its platform toward clinical validation and broader applications.

"These changes reflect the natural evolution of TetraKit Technologies," said the Board of Directors. "With early human trials on the horizon and increasing focus on automation, the new leadership structure will strengthen the Company's ability to deliver on its mission."

### **About TetraKit Technologies**

TetraKit Technologies is pioneering radiopharma start-up, dedicated to advancing next-generation theranostics via its proprietary, click-chemistry based TetraKit Platform. The Company focuses on delivering the technology needed for seamless and accessible radiolabeling of all targeting ligands with radiohalogens, and in particular astatine-211 for targeted alpha therapy.